Phibro Animal Health Corporation (PAHC)
USD 19.48
(4.73%)
USD 19.48
(4.73%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 2.41 Million USD | -92.59% |
| 2023 | 32.6 Million USD | -33.69% |
| 2022 | 49.17 Million USD | -9.58% |
| 2021 | 54.38 Million USD | 62.09% |
| 2020 | 33.55 Million USD | -38.66% |
| 2019 | 54.7 Million USD | -15.72% |
| 2018 | 64.9 Million USD | 0.46% |
| 2017 | 64.6 Million USD | -21.89% |
| 2016 | 82.7 Million USD | 37.19% |
| 2015 | 60.28 Million USD | 2044.52% |
| 2014 | -3.1 Million USD | -112.45% |
| 2013 | 24.89 Million USD | 256.81% |
| 2012 | 6.97 Million USD | 153.99% |
| 2011 | -12.92 Million USD | -130.69% |
| 2010 | 42.1 Million USD | 607.23% |
| 2009 | -8.3 Million USD | -477.27% |
| 2008 | 2.2 Million USD | 132.84% |
| 2007 | -6.7 Million USD | 48.85% |
| 2006 | -13.1 Million USD | 40.72% |
| 2005 | -22.1 Million USD | -271.32% |
| 2004 | 12.9 Million USD | 173.3% |
| 2003 | -17.6 Million USD | 66.02% |
| 2002 | -51.8 Million USD | -247.65% |
| 2001 | -14.9 Million USD | -247.52% |
| 2000 | 10.1 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 8.4 Million USD | 559.73% |
| 2024 Q4 | 752 Thousand USD | -91.05% |
| 2024 Q2 | 1.27 Million USD | 115.93% |
| 2024 FY | 2.41 Million USD | -92.59% |
| 2024 Q1 | -8 Million USD | -169.58% |
| 2023 Q2 | 7.21 Million USD | 86.98% |
| 2023 Q4 | 11.49 Million USD | 14.5% |
| 2023 Q3 | 10.04 Million USD | 39.28% |
| 2023 FY | 32.6 Million USD | -33.69% |
| 2023 Q1 | 3.85 Million USD | -48.59% |
| 2022 Q2 | 17.46 Million USD | 167.29% |
| 2022 FY | 49.17 Million USD | -9.58% |
| 2022 Q4 | 7.5 Million USD | -57.6% |
| 2022 Q3 | 17.68 Million USD | 1.28% |
| 2022 Q1 | 6.53 Million USD | -61.79% |
| 2021 Q3 | 12.16 Million USD | -5.0% |
| 2021 Q4 | 17.1 Million USD | 40.61% |
| 2021 Q2 | 12.8 Million USD | 4.06% |
| 2021 Q1 | 12.3 Million USD | 119.68% |
| 2021 FY | 54.38 Million USD | 62.09% |
| 2020 Q4 | 5.6 Million USD | -58.52% |
| 2020 FY | 33.55 Million USD | -38.66% |
| 2020 Q1 | 2.51 Million USD | -71.42% |
| 2020 Q2 | 11.89 Million USD | 372.92% |
| 2020 Q3 | 13.5 Million USD | 13.51% |
| 2019 FY | 54.7 Million USD | -15.72% |
| 2019 Q2 | 14.74 Million USD | -9.6% |
| 2019 Q3 | 14.84 Million USD | 0.68% |
| 2019 Q4 | 8.8 Million USD | -40.74% |
| 2019 Q1 | 16.31 Million USD | -26.18% |
| 2018 Q2 | 7.03 Million USD | -55.75% |
| 2018 Q1 | 15.89 Million USD | 3.19% |
| 2018 FY | 64.9 Million USD | 0.46% |
| 2018 Q4 | 22.1 Million USD | 11.39% |
| 2018 Q3 | 19.84 Million USD | 182.14% |
| 2017 Q3 | 23.64 Million USD | 76.22% |
| 2017 Q1 | 12.17 Million USD | -19.89% |
| 2017 FY | 64.6 Million USD | -21.89% |
| 2017 Q4 | 15.4 Million USD | -34.86% |
| 2017 Q2 | 13.41 Million USD | 10.18% |
| 2016 FY | 82.7 Million USD | 37.19% |
| 2016 Q4 | 15.2 Million USD | -18.18% |
| 2016 Q3 | 18.57 Million USD | -38.44% |
| 2016 Q2 | 30.17 Million USD | 60.92% |
| 2016 Q1 | 18.75 Million USD | 277.4% |
| 2015 Q3 | 19.42 Million USD | 26.1% |
| 2015 FY | 60.28 Million USD | 2044.52% |
| 2015 Q2 | 15.4 Million USD | -24.78% |
| 2015 Q4 | 4.96 Million USD | -74.42% |
| 2015 Q1 | 20.48 Million USD | 216.37% |
| 2014 Q2 | 2.3 Million USD | -60.6% |
| 2014 Q4 | -17.6 Million USD | -376.3% |
| 2014 Q1 | 5.84 Million USD | -2.27% |
| 2014 Q3 | 6.37 Million USD | 176.72% |
| 2014 FY | -3.1 Million USD | -112.45% |
| 2013 Q3 | 4.18 Million USD | -65.38% |
| 2013 Q2 | 12.07 Million USD | 63.9% |
| 2013 Q4 | 5.97 Million USD | 43.04% |
| 2013 Q1 | 7.36 Million USD | 0.0% |
| 2013 FY | 24.89 Million USD | 256.81% |
| 2012 FY | 6.97 Million USD | 153.99% |
| 2011 FY | -12.92 Million USD | -130.69% |
| 2010 Q2 | 32.5 Million USD | 261.11% |
| 2010 Q1 | 9 Million USD | -34.78% |
| 2010 FY | 42.1 Million USD | 607.23% |
| 2009 Q4 | 13.8 Million USD | 413.64% |
| 2009 Q3 | -4.4 Million USD | 50.56% |
| 2009 Q2 | -8.9 Million USD | -2.3% |
| 2009 FY | -8.3 Million USD | -477.27% |
| 2009 Q1 | -8.7 Million USD | -238.1% |
| 2008 Q4 | 6.3 Million USD | 151.22% |
| 2008 Q2 | 5.6 Million USD | 124.0% |
| 2008 Q1 | 2.5 Million USD | -63.77% |
| 2008 FY | 2.2 Million USD | 132.84% |
| 2008 Q3 | -12.3 Million USD | -319.64% |
| 2007 FY | -6.7 Million USD | 48.85% |
| 2007 Q4 | 6.9 Million USD | 1280.0% |
| 2007 Q2 | 2.2 Million USD | 113.5% |
| 2007 Q1 | -16.3 Million USD | -132.86% |
| 2007 Q3 | 500 Thousand USD | -77.27% |
| 2006 Q2 | -2 Million USD | 28.57% |
| 2006 Q3 | -1.4 Million USD | 30.0% |
| 2006 Q4 | -7 Million USD | -400.0% |
| 2006 FY | -13.1 Million USD | 40.72% |
| 2006 Q1 | -2.8 Million USD | 56.25% |
| 2005 Q2 | -7.6 Million USD | -7500.0% |
| 2005 FY | -22.1 Million USD | -271.32% |
| 2005 Q4 | -6.4 Million USD | -14.29% |
| 2005 Q1 | -100 Thousand USD | 98.92% |
| 2005 Q3 | -5.6 Million USD | 26.32% |
| 2004 Q3 | -400 Thousand USD | -101.88% |
| 2004 FY | 12.9 Million USD | 173.3% |
| 2004 Q1 | 1.3 Million USD | 117.81% |
| 2004 Q2 | 21.3 Million USD | 1538.46% |
| 2004 Q4 | -9.3 Million USD | -2225.0% |
| 2003 Q1 | -200 Thousand USD | 0.0% |
| 2003 Q3 | -2.3 Million USD | 70.51% |
| 2003 Q4 | -7.3 Million USD | -217.39% |
| 2003 FY | -17.6 Million USD | 66.02% |
| 2003 Q2 | -7.8 Million USD | -3800.0% |
| 2002 FY | -51.8 Million USD | -247.65% |
| 2001 FY | -14.9 Million USD | -247.52% |
| 2000 FY | 10.1 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 101.155% |
| Theratechnologies Inc. | -23.95 Million USD | 110.085% |
| Safety Shot Inc | -15.08 Million USD | 116.018% |
| Cosmos Health Inc. | -18.54 Million USD | 113.029% |
| Cronos Group Inc. | -73.96 Million USD | 103.266% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 100.241% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 105.725% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 51.143% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 139.201% |
| ProPhase Labs, Inc. | -16.78 Million USD | 114.396% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 149.969% |
| Dynavax Technologies Corporation | -6.38 Million USD | 137.815% |
| Radius Health, Inc. | -25.79 Million USD | 109.368% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 177.972% |
| Alvotech | -551.73 Million USD | 100.438% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 153.617% |
| Alpha Teknova, Inc. | -36.78 Million USD | 106.569% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 101.73% |
| SCYNEXIS, Inc. | 67.04 Million USD | 96.396% |
| Harrow Health, Inc. | -24.41 Million USD | 109.897% |
| Biofrontera Inc. | -20.13 Million USD | 112.001% |
| DURECT Corporation | -27.62 Million USD | 108.746% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -83.587% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 87.135% |
| OptiNose, Inc. | -35.48 Million USD | 106.809% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 89.898% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 130.699% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 138.476% |
| SIGA Technologies, Inc. | 68.06 Million USD | 96.451% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 79.888% |
| Shineco, Inc. | -22.44 Million USD | 110.762% |
| Procaps Group S.A. | 42.54 Million USD | 94.321% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 123.507% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 156.162% |
| Viatris Inc. | 54.7 Million USD | 95.583% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 153.617% |
| Rockwell Medical, Inc. | -8.43 Million USD | 128.629% |
| Incannex Healthcare Limited | -18.45 Million USD | 113.088% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 115.249% |
| Tilray Brands, Inc. | -244.98 Million USD | 100.986% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 94.983% |
| PetIQ, Inc. | 2.13 Million USD | -13.374% |
| Silver Spike Investment Corp. | 7.34 Million USD | 67.085% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 99.032% |
| Journey Medical Corporation | -3.85 Million USD | 162.704% |
| Alimera Sciences, Inc. | -20.13 Million USD | 112.001% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 129.596% |
| Assertio Holdings, Inc. | -331.94 Million USD | 100.728% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 136.646% |
| Embecta Corp. | 70.4 Million USD | 96.568% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 112.045% |
| Procaps Group, S.A. | 42.54 Million USD | 94.321% |
| PainReform Ltd. | -9.34 Million USD | 125.856% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 101.507% |
| Hempacco Co., Inc. | -13.12 Million USD | 118.406% |
| Talphera, Inc. | -18.39 Million USD | 113.133% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 94.241% |
| Alvotech | -551.73 Million USD | 100.438% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 99.26% |
| Kamada Ltd. | 8.28 Million USD | 70.835% |
| Indivior PLC | 2 Million USD | -20.8% |
| Currenc Group, Inc. | -15.3 Million USD | 115.784% |
| Evoke Pharma, Inc. | -7.79 Million USD | 131.005% |
| Flora Growth Corp. | -57.03 Million USD | 104.236% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 112.045% |
| Evolus, Inc. | -61.68 Million USD | 103.917% |
| HUTCHMED (China) Limited | 100.78 Million USD | 97.603% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 98.243% |
| Akanda Corp. | -32.27 Million USD | 107.486% |